Literature DB >> 23730321

Daptomycin-nonsusceptible, vancomycin-intermediate, methicillin-resistant Staphylococcus aureus endocarditis.

Ryan Yu1, Suzanne E Dale, Deborah Yamamura, Vida Stankus, Christine Lee.   

Abstract

Due to the emergence of Staphylococcus aureus with reduced vancomycin susceptibility, newer antibiotics, including daptomycin, have been used to treat methicillin-resistant S aureus infections. Daptomycin is a cyclic lipopeptide that is approved to treat S aureus bacteremia and right-sided endocarditis, and reports of S aureus with reduced susceptibility to daptomycin are infrequent. To our knowledge, the present report describes the first Canadian case of daptomycin-nonsusceptible, vancomycin-intermediate S aureus infection.

Entities:  

Keywords:  Daptomycin nonsusceptible; Endocarditis; Methicillin-resistant Staphylococcus aureus; Vancomycin intermediate resistance

Year:  2012        PMID： 23730321      PMCID： PMC3403664          DOI： 10.1155/2012/138470

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN： 1712-9532            Impact factor:   2.471


  23 in total

1.  Development of a Canadian standardized protocol for subtyping methicillin-resistant Staphylococcus aureus using pulsed-field gel electrophoresis.

Authors:  M R Mulvey; L Chui; J Ismail; L Louie; C Murphy; N Chang; M Alfa
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

2.  Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis.

Authors:  Kathleen Julian; Klaudia Kosowska-Shick; Cynthia Whitener; Martin Roos; Harald Labischinski; Aileen Rubio; Leslie Parent; Lois Ednie; Laura Koeth; Tatiana Bogdanovich; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

3.  A preliminary guideline for the assignment of methicillin-resistant Staphylococcus aureus to a Canadian pulsed-field gel electrophoresis epidemic type using spa typing.

Authors:  George R Golding; Jennifer L Campbell; Dave J Spreitzer; Joe Veyhl; Kathy Surynicz; Andrew Simor; Michael R Mulvey
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-07       Impact factor: 2.471

Review 4.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Authors:  Michael Rybak; Ben Lomaestro; John C Rotschafer; Robert Moellering; William Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine
Journal:  Am J Health Syst Pharm       Date:  2009-01-01       Impact factor: 2.637

5.  Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus.

Authors:  M K Hayden; K Rezai; R A Hayes; K Lolans; J P Quinn; R A Weinstein
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

6.  Methicillin-resistant Staphylococcus aureus endocarditis and de novo development of daptomycin resistance during therapy.

Authors:  L Twele; E Moyen; K Zhang; B Dalton; D Church; J Conly
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

7.  A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital.

Authors:  M Wootton; R A Howe; R Hillman; T R Walsh; P M Bennett; A P MacGowan
Journal:  J Antimicrob Chemother       Date:  2001-04       Impact factor: 5.790

8.  Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function.

Authors:  George Sakoulas; George M Eliopoulos; Vance G Fowler; Robert C Moellering; Richard P Novick; Natalie Lucindo; Michael R Yeaman; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

Review 9.  Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance.

Authors:  K Hiramatsu
Journal:  Lancet Infect Dis       Date:  2001-10       Impact factor: 25.071

10.  Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.

Authors:  Longzhu Cui; Eiji Tominaga; Hui-Min Neoh; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191
View more
  5 in total

Review 1.  Daptomycin non-susceptible, vancomycin-intermediate Staphylococcus aureus endocarditis treated with ceftaroline and daptomycin: case report and brief review of the literature.

Authors:  Sanjiv M Baxi; Dominic Chan; Vivek Jain
Journal:  Infection       Date:  2015-03-25       Impact factor: 3.553

Review 2.  Mechanisms of infective endocarditis: pathogen-host interaction and risk states.

Authors:  Karl Werdan; Sebastian Dietz; Bettina Löffler; Silke Niemann; Hasan Bushnaq; Rolf-Edgar Silber; Georg Peters; Ursula Müller-Werdan
Journal:  Nat Rev Cardiol       Date:  2013-11-19       Impact factor: 32.419

3.  Prevalence of Slow-Growth Vancomycin Nonsusceptibility in Methicillin-Resistant Staphylococcus aureus.

Authors:  Yuki Katayama; Takuya Azechi; Motoyasu Miyazaki; Tohru Takata; Miwa Sekine; Hidehito Matsui; Hideaki Hanaki; Koji Yahara; Hiroshi Sasano; Kota Asakura; Tomoiku Takaku; Tomonori Ochiai; Norio Komatsu; Henry F Chambers
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

Review 4.  Proteomic Applications in Antimicrobial Resistance and Clinical Microbiology Studies.

Authors:  Ehsaneh Khodadadi; Elham Zeinalzadeh; Sepehr Taghizadeh; Bahareh Mehramouz; Fadhil S Kamounah; Ehsan Khodadadi; Khudaverdi Ganbarov; Bahman Yousefi; Milad Bastami; Hossein Samadi Kafil
Journal:  Infect Drug Resist       Date:  2020-06-16       Impact factor: 4.003

5.  Single nucleotide polymorphism leads to daptomycin resistance causing amino acid substitution-T345I in MprF of clinically isolated MRSA strains.

Authors:  Masaki Nakamura; Hayato Kawada; Hiroki Uchida; Yusuke Takagi; Shuichi Obata; Ryotaro Eda; Hideaki Hanaki; Hidero Kitasato
Journal:  PLoS One       Date:  2021-01-22       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.